{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:21:03Z","timestamp":1781288463961,"version":"3.54.1"},"reference-count":34,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>OBJECTIVE<\/jats:bold> To evaluate clinical signs, endocrine test results, and pituitary tumor size for dogs with medically managed pituitary-dependent hyperadrenocorticism (PDH) and macroadenoma following 6 months of concurrent treatment with pasireotide.<\/jats:p>\n<jats:p><jats:bold>DESIGN<\/jats:bold> Prospective case series.<\/jats:p>\n<jats:p><jats:bold>ANIMALS<\/jats:bold> 9 client-owned dogs with PDH and macroadenoma in which PDH had been successfully managed with adrenal-directed treatment (trilostane or mitotane).<\/jats:p>\n<jats:p><jats:bold>PROCEDURES<\/jats:bold> Dogs were given pasireotide (0.03 mg\/kg [0.014 mg\/lb], SC, q 12 h) for 6 months, while adrenal-directed treatment was continued. Physical examination, basic clinicopathologic testing, ACTH stimulation testing, and plasma ACTH concentration measurement were performed before (baseline) and 3 and 6 months after treatment began. Measurements of pituitary gland volume and pituitary gland-to-brain ratio were performed via MRI at baseline and 6 months after treatment began.<\/jats:p>\n<jats:p><jats:bold>RESULTS<\/jats:bold> No dog developed neurologic abnormalities or signs of adverse effects during the study period. No differences from baseline were identified in clinicopathologic values, ACTH stimulation test results, or plasma ACTH concentration at the 3- or 6-month assessment points. After 6 months of pasireotide treatment, 6 dogs had decreases in MRI-measured values, and 3 had increases.<\/jats:p>\n<jats:p><jats:bold>CONCLUSIONS AND CLINICAL RELEVANCE<\/jats:bold> Pasireotide as administered in this study had no noted adverse effects on dogs with PDH and macroadenoma successfully managed with standard treatment. Placebo-controlled, randomized studies are needed to determine whether pasireotide protects from the development of neurologic signs or improves outcome in dogs with pituitary macroadenomas.<\/jats:p>","DOI":"10.2460\/javma.252.11.1403","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T03:23:14Z","timestamp":1526613794000},"page":"1403-1408","source":"Crossref","is-referenced-by-count":8,"title":["Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013\u20132015)"],"prefix":"10.2460","volume":"252","author":[{"given":"Maya","family":"Lottati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Bruyette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Neurosurg Focus","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.3171\/2014.10.FOCUS14683","article-title":"Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature","volume":"38","author":"Seltzer","year":"2015"},{"key":"ref2","series-title":"Horm Res","first-page":"140","article-title":"Cushing's disease in dogs and humans","volume":"71","author":"de Bruin","year":"2009"},{"key":"ref3","series-title":"Vet Surg","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1532-950X.2014.12146.x","article-title":"Transsphenoidal surgery using a high definition video telescope for pituitary adenomas in dogs with pituitary dependent hypercortisolism: methods and results","volume":"43","author":"Mamelak","year":"2014"},{"key":"ref4","series-title":"Res Vet Sci","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.rvsc.2009.07.005","article-title":"Corticotroph adenoma in the dog: pathogenesis and new therapeutic possibilities","volume":"88","author":"Castillo","year":"2010"},{"key":"ref5","series-title":"Endocr Rev","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1210\/edrv.20.2.0358","article-title":"The molecular pathogenesis of corticotroph tumors","volume":"20","author":"Dahia","year":"1999"},{"key":"ref6","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0303-7207(02)00280-0","article-title":"Glucocorticoid receptors and Cushing's disease","volume":"197","author":"Lamberts","year":"2002"},{"key":"ref7","series-title":"Proc Assoc Am Physicians","first-page":"296","article-title":"Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel dominant-negative glucocorticoid receptor mutation","volume":"108","author":"Karl","year":"1996"},{"key":"ref8","series-title":"J Clin Endocrinol Metab","first-page":"124","article-title":"Nelson's syndrome associated with somatic frame shift mutation in the glucocorticoid receptor gene","volume":"81","author":"Karl","year":"1996"},{"key":"ref9","series-title":"Domest Anim Endocrinol","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.domaniend.2008.10.002","article-title":"Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic\u2013pituitary axis","volume":"36","author":"Teshima","year":"2009"},{"key":"ref10","series-title":"Domest Anim Endocrinol","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.domaniend.2008.08.002","article-title":"Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease","volume":"36","author":"Teshima","year":"2009"},{"key":"ref11","series-title":"Prog Brain Res","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0079-6123(08)61217-0","article-title":"Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with ldeprenyl","volume":"106","author":"Bruyette","year":"1995"},{"key":"ref12","series-title":"Curr Gene Ther","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/156652306775515556","article-title":"The neuroendocrine system as a model to evaluate experimental gene therapy","volume":"6","author":"Here\u00f1\u00fa","year":"2006"},{"key":"ref13","series-title":"Gene Ther","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/sj.gt.3302870","article-title":"Restorative effect of insulin-like growth factor-I gene therapy in the hypothalamus of senile rats with dopaminergic dysfunction","volume":"14","author":"Here\u00f1\u00fa","year":"2007"},{"key":"ref14","series-title":"Expert Opin Pharmacother","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/14656566.1.3.555","article-title":"Cabergoline","volume":"1","author":"Colao","year":"2000"},{"key":"ref15","series-title":"Endocrinology","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1210\/en.2008-0244","article-title":"Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine Cushing's disease","volume":"149","author":"de Bruin","year":"2008"},{"key":"ref16","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004"},{"key":"ref17","series-title":"Front Neuroendocrinol","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0091-3022(03)00012-8","article-title":"Molecular defects in the pathogenesis of pituitary tumors","volume":"24","author":"Levy","year":"2003"},{"key":"ref18","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1210\/jcem-71-6-1427","article-title":"Clonal origin of pituitary adenomas","volume":"71","author":"Herman","year":"1990"},{"key":"ref19","series-title":"Endocrinol Metab Clin North Am","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ecl.2014.10.006","article-title":"Medical treatment of Cushing disease: new targets, new hope","volume":"44","author":"Fleseriu","year":"2015"},{"key":"ref20","series-title":"Neuroendocrinology","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000327429","article-title":"Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease","volume":"94","author":"Castillo","year":"2011"},{"key":"ref21","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/jvim.12192","article-title":"Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal)","volume":"27","author":"Behrend","year":"2013"},{"key":"ref22","series-title":"Canine and feline endocrinology","first-page":"377","article-title":"Canine hyperadrenocorticism","author":"Behrend","year":"2015"},{"key":"ref23","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2460\/ajvr.67.11.1865","article-title":"Thin-slice three-dimensional gradient-echo magnetic resonance imaging of the pituitary gland in healthy dogs","volume":"67","author":"van der Vlugt-Meijer","year":"2006"},{"key":"ref24","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0303-7207(02)00282-4","article-title":"Imaging of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism","volume":"197","author":"van der Vlugt-Meijer","year":"2002"},{"key":"ref25","series-title":"Horm Metab Res","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1055\/s-0042-101347","article-title":"A single-center 10-year experience with pasireotide in Cushing's disease: patients\u2019 characteristics and outcome","volume":"48","author":"Trementino","year":"2016"},{"key":"ref26","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/j.1939-1676.2007.tb03060.x","article-title":"Survival, neurologic response, and prognostic factors in dogs with pituitary masses treated with radiation therapy and untreated dogs","volume":"21","author":"Kent","year":"2007"},{"key":"ref27","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009"},{"key":"ref28","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012"},{"key":"ref29","series-title":"Toxicol Appl Pharmacol","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.taap.2015.05.004","article-title":"Osilodrostat (LCI699), a potent 11\u03b2-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: a 13-week study in rats","volume":"286","author":"Li","year":"2015"},{"key":"ref30","series-title":"Endocrine","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1385\/ENDO:28:1:093","article-title":"Treatment of pituitary tumors: somatostatin","volume":"28","author":"Tichomirowa","year":"2005"},{"key":"ref31","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014"},{"key":"ref32","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM195807242590403","article-title":"ACTH-producing tumor of the pituitary gland","volume":"259","author":"Nelson","year":"1958"},{"key":"ref33","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jc.2006-1328","article-title":"Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome","volume":"92","author":"Assi\u00e9","year":"2007"},{"key":"ref34","series-title":"J Am Vet Med Assoc","first-page":"1268","article-title":"One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism","volume":"208","author":"Bertoy","year":"1996"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/252\/11\/javma.252.11.1403.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/252\/11\/javma.252.11.1403.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/252\/11\/javma.252.11.1403.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:58:08Z","timestamp":1741348688000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/252\/11\/javma.252.11.1403.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":34,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/javma.252.11.1403","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}